| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Dynavax Technologies Corporation |
| 717 Potter Street, Suite 100, Berkeley, CA 94710 * (510) 848-5100 |
| Business Description | The company is a biopharmaceutical company focused on discovering, developing and commercializing innovative products to treat and prevent allergies, infectious diseases, cancer and chronic inflammatory diseases. |
|
Filing Information Not yet | |||
| To Trade As | DVAX (NASNTL) | Industry | Pharmaceutical (SIC 2836) |
| Type of Stock Offered | Common Shares | Filing Date | 12/5/00 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $75,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Banc of America Securities LLC | Lead Manager | (415) 627-2100 |
| UBS Warburg LLC | Co-manager |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | 9/30/99 | 9/30/00 | |
| Revenues | - | 0.000 | 0.000 | 0.000 | 0.450 | 0.155 | 1.493 |
| Income from Oper. | - | -0.222 | -3.746 | -7.094 | -6.995 | -5.310 | -6.583 |
| Net Income | - | -0.206 | -3.505 | -6.778 | -6.559 | -4.985 | -5.916 |
| E.P.S | - | -1.890 | -5.290 | -6.640 | -4.500 | -3.560 | -11.210 |
| Revenue Growth (%) | - | - | - | - | 863.23 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -5.36 | -5.19 | -5.80 | ||||
| Cash Flow - Inv. | 4.94 | 0.36 | -14.74 | ||||
| Cash Flow - Fin. | 0.87 | -0.10 | 25.32 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/00 | Financial Ratios | ||||
| Total Assets | 29.04 | Current Assets | 28.19 | Current Ratio | 16.76 |
| Total Liab. | 50.93 | Current Liab. | 1.68 | Debt Ratio | 175.41% |
| Total Equity | -21.90 | Working Cap. | 26.51 | Debt to Equity Ratio | - |
| Cash | 11.52 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to obtain additional capital and increase financial flexibility, to increase the size of staff to implement product development programs, lease additional facilities to house operations and establish manufacturing capabilities. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Morrison & Foerster |
| Bank's Law Firm | Latham & Watkins |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Sanderling Venture Partners IV, L.P. | 13.40 | |
| InterWest Partners V, L.P. | 13.40 | |
| Alta California Partners, L.P. | 13.40 | |
| Bank of America Ventures | 8.80 | |
| Note: represents ownership of 5% or more prior to the offering. | ||